Return to the workforce following infective endocarditis—A nationwide cohort study - 09/12/17
, Kristian Kragholm, MD, PhD b, Michael Dalager-Pedersen, MD, PhD c, Rasmus Rørth, MD a, Søren L. Kristensen, MD, PhD a, Mavish S. Chaudry, MD d, Nana Valeur, MD, PhD e, Lauge Østergaard, MB a, Christian Torp-Pedersen, MD, DMSc f, Gunnar H. Gislason, MD, PhD d, g, h, Lars Køber, MD, DMSc a, Emil L. Fosbøl, MD, PhD aAbstract |
Background |
The ability to return to work after infective endocarditis (IE) holds important socioeconomic consequences for both patients and society, yet data on this issue are sparse. We examined return to the workforce and associated factors in IE patients of working age.
Methods |
Using Danish nationwide registries, we identified 1,065 patients aged 18-60 years with a first-time diagnosis of IE (1996-2013) who were part of the workforce prior to admission and alive at discharge.
Results |
One year after discharge, 765 (71.8%) patients had returned to the workforce, 130 (12.2%) were on paid sick leave, 76 (7.1%) received disability pension, 23 (2.2%) were on early retirement, 65 (6.1%) had died, and 6 (0.6%) had emigrated. Factors associated with return to the workforce were identified using multivariable logistic regression. Younger age (18-40 vs 56-60 years; odds ratio, 2.85; 95% CI, 1.71-4.76) and higher level of education (higher educational level vs basic school; 5.47, 2.05-14.6) and income (highest quartile vs lowest; 3.17, 1.85-5.46) were associated with return to the workforce. Longer length of hospital stay (>90 vs 14-30 days; 0.16, 0.07-0.38); stroke during IE admission (0.38, 0.21-0.71); and a history of chronic kidney disease (0.29, 0.11-0.75), chronic obstructive pulmonary disease (0.31, 0.13-0.71), and malignancy (0.39, 0.22-0.69) were associated with a lower likelihood of returning to the workforce.
Conclusions |
Seven of 10 patients who were part of the workforce prior to IE and alive at discharge were part of the workforce 1 year later. Younger age, higher socioeconomic status, and absence of major comorbidities were associated with return to the workforce.
Le texte complet de cet article est disponible en PDF.Plan
| Blase A. Carabello, MD, served as guest editor for this article. |
Vol 195
P. 130-138 - janvier 2018 Retour au numéro
Article précédent
- Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial
- Nathan P. Clark, James D. Douketis, Vic Hasselblad, Sam Schulman, Andrei L. Kindzelski, Thomas L. Ortel, for The BRIDGE Investigators
- Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project
- Paul L. Hess, Kevin Kennedy, Michael Cowherd, Salim S. Virani, Frederick A. Masoudi, Ann Marie Navar, Robert W. Yeh, P. Michael Ho, Thomas M. Maddox
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?